272 Capital LP decreased its position in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 47.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,325 shares of the company's stock after selling 65,855 shares during the quarter. 272 Capital LP owned approximately 0.06% of Enfusion worth $696,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP raised its stake in Enfusion by 57.5% in the second quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company's stock worth $4,466,000 after buying an additional 191,436 shares in the last quarter. Impax Asset Management Group plc grew its holdings in Enfusion by 25.4% in the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company's stock worth $6,424,000 after purchasing an additional 136,948 shares during the last quarter. Scalar Gauge Management LLC increased its position in shares of Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company's stock worth $5,227,000 after purchasing an additional 110,000 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Enfusion during the 3rd quarter valued at $892,000. Finally, PDT Partners LLC acquired a new stake in shares of Enfusion in the 3rd quarter worth $867,000. Hedge funds and other institutional investors own 81.05% of the company's stock.
Enfusion Stock Performance
ENFN stock traded down $0.08 on Friday, hitting $9.94. 296,370 shares of the company's stock were exchanged, compared to its average volume of 564,756. The firm has a 50 day moving average price of $9.32 and a two-hundred day moving average price of $8.89. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $10.45. The stock has a market cap of $1.28 billion, a P/E ratio of 248.56, a price-to-earnings-growth ratio of 3.72 and a beta of 0.93.
About Enfusion
(
Free Report)
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
Featured Stories
Before you consider Enfusion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enfusion wasn't on the list.
While Enfusion currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
